Discussion:
The fold increase in GMT was higher in test group as compared to control in all trials, indicating effective immunogenicity of CYD-TDV. Another trend found in all trials is that the third dose of CYD-TDV elicited only a slight increase in GMT from the second. Finally, patients in some trials
exhibited a more robust immune response( higher peak GMT) than others. These trials had higher baseline seropositivity rates, which led to stimulation of secondary immune response by the vaccine. Safety results were satisfactory in all trials in which most severe side effects were unrelated to the vaccine.
Conclusion:
CYD-TDV is both effective and safe for patients in endemic regions. This gives promise for further development and large-scale research on this vaccine to assess its efficacy in decreasing dengue prevalence and, its pervasive implementation in Indonesia.